Lopinavir/ritonavir: a review of its use in the management of HIV infection.
about
HIV protease inhibitors do not cause the accumulation of prelamin A in PBMCs from patients receiving first line therapy: the ANRS EP45 "aging" studySequential population pharmacokinetic modeling of lopinavir and ritonavir in healthy volunteers and assessment of different dosing strategiesNovel strategies in the use of lopinavir/ritonavir for the treatment of HIV infection in children.CYP3A4-mediated lopinavir bioactivation and its inhibition by ritonavir.The interaction between artemether-lumefantrine and lopinavir/ritonavir-based antiretroviral therapy in HIV-1 infected patients.HIV protease inhibitors and nuclear lamin processing: getting the right bells and whistles.Safety and efficacy after switch to a saquinavir-containing antiretroviral regimen in protease inhibitor pretreated HIV-positive patients.Deep sequencing reveals minor protease resistance mutations in patients failing a protease inhibitor regimen.Lopinavir/ritonavir in the treatment of HIV-1 infection: a review.Pediatric HIV infection: the state of antiretroviral therapy.Ritonavir blocks AKT signaling, activates apoptosis and inhibits migration and invasion in ovarian cancer cells.Antiretroviral drug toxicity in relation to pharmacokinetics, metabolic profile and pharmacogenetics.Ritonavir-boosted protease inhibitors in HIV therapy.The lipid-lowering effect of tenofovir/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial.Amending HIV Drugs: A Novel Small-Molecule Approach To Target Lupus Anti-DNA AntibodiesCoadministration with lopinavir and ritonavir decreases exposure to BILR 355, a nonnucleoside reverse transcriptase inhibitor, in healthy volunteers.Uveitis associated with concurrent administration of rifabutin and lopinavir/ritonavir (Kaletra).Effects of ritonavir-boosted lopinavir on the pharmacokinetics of quinine.Dual-stimuli responsive injectable microgel/solid drug nanoparticle nanocomposites for release of poorly soluble drugs.Analysis of HIV protease binding pockets based on 3D shape and electrostatic potential descriptors.Analysis of possible drug-drug interactions between ritonavir and other antiretrovirals in a section of the private health care sector in South Africa.The experience of patients taking the lopinavir/ritonavir (LPV/r) tablet compared with the LPV/r soft-gel capsule in Zambia
P2860
Q34534986-05D4F8B3-6001-4117-BFC7-BA4E6AD87B58Q35005222-7090E5B9-5589-4F12-A1F7-D4C60CFF4335Q35557224-002D5D47-781F-478C-A85C-6F26A07328FEQ35647173-5C21174A-2C5A-48B9-BA88-151AB69B359EQ35906361-8EB6ED8C-C85A-4BEB-926F-E7CB1AC00A2EQ35956709-153DD784-0C0F-4BB3-806F-334E357027FBQ35958784-D427DA8A-C9B5-40E6-862D-96A204A647F3Q36023047-46C2CDCB-C503-45F2-8BB2-5003947459A9Q37052827-D514FEA2-799E-4E70-86DE-BA0D3422B9C1Q37124873-EE2116B2-17C9-4A4E-84E7-59F484A96098Q37215121-47F21791-B97B-4201-BBBA-61FD541E5F0DQ37866298-6D66D501-91AF-49D4-BE28-BD5619EA057FQ37866319-9FF10A52-6E8B-47BA-9376-3BF6BF2276BCQ41337231-6AA981B5-E435-43A7-A4BC-70962F7315ABQ41406224-CEF4B835-A194-412A-B010-105CF9940081Q43774080-0DE2F522-4F14-4446-93B6-A27F72424936Q46929981-3AAEEB33-58D0-45C0-B2FA-02B68E45A565Q48006398-26C56568-4E6E-4E7D-8708-79851BA965F4Q48337638-7630C0E3-E992-4E98-A947-1DA09BDAED96Q51609848-1B476C2F-E000-4D12-843D-A1ADC40A124DQ55208876-3E0A8420-5B70-40C3-B7D1-E9430DB6DA18Q58432314-4FAF6032-82BC-43B0-8C89-9101E4D353BB
P2860
Lopinavir/ritonavir: a review of its use in the management of HIV infection.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Lopinavir/ritonavir: a review of its use in the management of HIV infection.
@ast
Lopinavir/ritonavir: a review of its use in the management of HIV infection.
@en
Lopinavir/ritonavir: a review of its use in the management of HIV infection.
@nl
type
label
Lopinavir/ritonavir: a review of its use in the management of HIV infection.
@ast
Lopinavir/ritonavir: a review of its use in the management of HIV infection.
@en
Lopinavir/ritonavir: a review of its use in the management of HIV infection.
@nl
prefLabel
Lopinavir/ritonavir: a review of its use in the management of HIV infection.
@ast
Lopinavir/ritonavir: a review of its use in the management of HIV infection.
@en
Lopinavir/ritonavir: a review of its use in the management of HIV infection.
@nl
P1433
P1476
Lopinavir/ritonavir: a review of its use in the management of HIV infection.
@en
P2093
Vicki Oldfield
P304
P356
10.2165/00003495-200666090-00012
P577
2006-01-01T00:00:00Z
P6179
1009752545